Stock Analysis

FALCO HOLDINGS Third Quarter 2025 Earnings: EPS: JP¥54.46 (vs JP¥59.32 in 3Q 2024)

TSE:4671
Source: Shutterstock

FALCO HOLDINGS (TSE:4671) Third Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥11.4b (up 3.4% from 3Q 2024).
  • Net income: JP¥578.0m (down 11% from 3Q 2024).
  • Profit margin: 5.1% (down from 5.9% in 3Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: JP¥54.46 (down from JP¥59.32 in 3Q 2024).
earnings-and-revenue-history
TSE:4671 Earnings and Revenue History February 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

FALCO HOLDINGS shares are up 2.1% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on FALCO HOLDINGS' balance sheet.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:4671

FALCO HOLDINGS

A medical service company, provides clinical testing and dispensing pharmacy services to medical institutions and companies in Japan.

Flawless balance sheet 6 star dividend payer.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.1226% overvalued
Jonataninho
Jonataninho
Community Contributor